CPH Stock Overview
A clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Histogen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.73 |
| 52 Week High | US$1.30 |
| 52 Week Low | US$0.45 |
| Beta | 1.15 |
| 11 Month Change | 0% |
| 3 Month Change | -13.01% |
| 1 Year Change | -23.66% |
| 33 Year Change | -95.53% |
| 5 Year Change | n/a |
| Change since IPO | -99.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -1.8% |
| 1Y | -23.7% | -15.4% | 13.6% |
Return vs Industry: CPH exceeded the German Biotechs industry which returned -24.7% over the past year.
Return vs Market: CPH underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| CPH volatility | |
|---|---|
| CPH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CPH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Susan Knudson | www.histogen.com |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases.
Histogen Inc. Fundamentals Summary
| CPH fundamental statistics | |
|---|---|
| Market cap | €1.33m |
| Earnings (TTM) | -€11.33m |
| Revenue (TTM) | €17.39k |
76.4x
P/S Ratio-0.1x
P/E RatioIs CPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPH income statement (TTM) | |
|---|---|
| Revenue | US$19.00k |
| Cost of Revenue | US$5.03m |
| Gross Profit | -US$5.01m |
| Other Expenses | US$7.37m |
| Earnings | -US$12.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | -26,347.37% |
| Net Profit Margin | -65,142.11% |
| Debt/Equity Ratio | 0% |
How did CPH perform over the long term?
See historical performance and comparison